ALXN Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Stats
Dzisiejszy wolumen	3.00
Średni wolumen	4.22M
Kapitalizacja rynkowa	0.00
EPS	$0 ( 2021-07-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	59.23
ATR14	$1.935 (1.06%)

Insider Trading

Date	Person	Action	Amount	type
2021-07-21	Coughlin Christopher J	Sell	42 347	Common Stock, par value $.0001 per share
2021-07-21	Coughlin Christopher J	Sell	2 294	Option to Purchase Common Stock
2021-07-21	Coughlin Christopher J	Sell	2 706	Option to Purchase Common Stock
2021-07-21	Coughlin Christopher J	Sell	2 343	Option to Purchase Common Stock
2021-07-21	Sarin Aradhana	Sell	120 253	Common Stock, par value $.0001 per share

INSIDER POWER
0.00
Last 100 transactions
Buy: 1 094 307 \| Sell: 1 860 897

Wolumen Korelacja

Długi: 0.13 (neutral)

Krótki: 0.11 (neutral)

Signal:(52.183) Neutral

Alexion Pharmaceuticals, Korelacja

10 Najbardziej pozytywne korelacje
CREC	0.977
FLXS	0.977
PRSR	0.976
LDHA	0.976
PWUP	0.973
MSDAU	0.973
CRZN	0.972
VLAT	0.97
FXCO	0.968
TIOAU	0.967

10 Najbardziej negatywne korelacje
MESA	-0.979
MBIO	-0.979
JG	-0.977
MLKN	-0.975
FWRD	-0.975
RENT	-0.974
GERN	-0.974
NXTC	-0.974
WKEY	-0.972
ATHA	-0.971

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Alexion Pharmaceuticals, Korelacja - Waluta/Towar

0.56
( weak )

0.82
( strong )

-0.22
( neutral )

0.43
( neutral )

0.58
( weak )

-0.73
( moderate negative )

Alexion Pharmaceuticals, Finanse

Annual	2020
Przychody:	$6.07B
Zysk brutto:	$5.52B (90.88 %)
EPS:	$2.74

FY	2020
Przychody:	$6.07B
Zysk brutto:	$5.52B (90.88 %)
EPS:	$2.74

FY	2019
Przychody:	$4.99B
Zysk brutto:	$4.60B (92.10 %)
EPS:	$10.77

FY	2018
Przychody:	$4.13B
Zysk brutto:	$3.76B (90.94 %)
EPS:	$0.348

Financial Reports:

No articles found.

Alexion Pharmaceuticals,

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.